You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Automated Point-of-Care Identification of Innocent Still's Murmur in Children

    SBC: AUSCULTECH DX LLC            Topic: NHLBI

    PROJECT SUMMARY The overall goal of the proposed research and technology transfer effort is to develop a low cost point of care mobile device based technology for automated identification of Stillandapos s murmur the most common innocent benign and harmless heart murmur of childhood This novel technology could reduce the current rate of over a million children unnecessarily referred to pedia ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Whole Brain Nanoscale Preservation Imaging

    SBC: Nectome Inc.            Topic: 101

    Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Small, high-affinity ligands for array tomography

    SBC: ARATOME, LLC            Topic: 101

    DESCRIPTION provided by applicant Neurodegenerative diseases are among the most expensive disruptive and least well treated of human maladies arguably because they are not well understood Array tomography AT is a method for tissue imaging with resolution in all three dimensions sufficient to resolve individual synapses and provide quantitative characterization ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Behavioral Activation Mobile App for depressed Latinos

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: 102

    DESCRIPTION provided by applicant Treatment for depression is a core health disparity for Latinos in the U S Although U S Latinos are more likely than non Hispanic Whites to experience depression Alegria et al U S Latinos are less than half as likely as Whites to receive evidence based care for depression Lagomasino et al Latinos with elevated depressive symptoms are mos ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Peptide Based Therapy for Lung Fibrosis

    SBC: Novici Biotech LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Real Time Oxygen Monitoring for Tissue Health Peripheral Artery Disease Application

    SBC: PROFUSA, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioid dependent patients Over million people in the US are addicted to opiates Providing effective agonist therapy methadone or buprenorphine coupled with behavioral counseling greatly improves outcomes reduces morbidity and reduces societal costs Methadone maintenance treatment has been limit ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction

    SBC: MOLECULAR EXPRESS, INC            Topic: R42

    DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

    SBC: REMD BIOTHERAPEUTICS INC.            Topic: NIDDK

    DESCRIPTION provided by applicant Fast Track Insulin remains the primary and often the only treatment for type diabetes mellitus T D However it is associated with chronic iatrogenic hyperinsulinemia secondary hyperlipidemia higher incidence and severity of cardiovascular complications and life threatening hypoglycemia events A higher mortality vs due to cardiovascular ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government